Accueil   Diary - News   All news New members

New members



DEINOVE is a French biotechnology company pioneering the exploration of the “microbial dark matter”. By revealing the metabolic potential of rare bacteria or classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance.


The new therapies discovered and developed by DEINOVE target superbugs that cause life-threatening infections which are now spreading at high speed.  


DEINOVE is conducting several development programs, of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infections, a World primary emergency. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.


Based in Montpellier, DEINOVE is listed on EURONEXT GROWTH® since 2010. The Company has more than 50 employees and leans on a world class network of academic, technological, industrial and institutional partners.





At Nexbiome Therapeutics, we define the microbiome as an ecosystem of microorganisms, the composition of which predisposes to health or to illness. Consequently, we are convinced that the microbiome represents the reservoir of therapeutic solutions for the future of human health.

Our mission is to identify the best research projects and turn them into biotech companies that will bring innovative health solutions to the market. Our ambition is to contribute to the emergence of global champions in every therapeutic segment for which health through the microbiome makes sense.

Our platform of competences brings together three key areas:

  • Scientific business development : assessment of innovative projects in relation to patient’s need and the scientific state-of-the-art,
  • Project engineering: Complete control over pharmaceutical development, from discovery to clinical phases,
  • Financial engineering: Finance engineering on equity and via financial partners.





Infodream is an editor-integrator of MES (Manufacturing Execution System).

An expert in industrial process control, Infodream develops the Qualaxy Suite, an innovative software suite for quality and productivity in industry.


Our expertise covers the following :

- consolidation of production and laboratory controls

- process validation workflow, timestamp

- monitoring of qualifications and multi-skilling

- data collection, full traceability, electronic signatures

- electronic work instructions

- acceptance of batches and AQLs (Acceptable Quality Levels)

- real-time SPC monitoring

- continuous production splitting


Infodream offer services like : training, consultancy, change management facilitation, quality and statistical analysis expertise.

Infodream works with some of the biggest names in the medical and pharmaceutical industry: Mölnlycke Health Care, Macopharma, Biomérieux, Fresenius Kabi, Novasep, etc.





Since 1987, IMIS – The Management Institute for Healthcare Industries – has been providing a quality business education to young professionals with scientific/medical backgrounds. IMIS students gain general business knowledge and skills and specialize in either Marketing or Regulatory Affairs. Upon graduation, students obtain a  Master of Science (MSc)« « International Manager for Health Care Industries ».





Specialized in genomic analysis, BIOMNIGENE is able to secure, validate the effect, the impact of a product on life or authenticate them.  We can answer to medical, environmental and industrial (pharmaceutical, agro-food, cosmetics) issues to  such as :

  • Intestinal, skin, vaginal, lung, soil microbiomes analysis
  • Identification, quantification authentication of species in a pur sample or in a mix (micro-organisms, virus, meat, fish…)
  • Antibody sequencing and safeguarding of hybridoma lines of special interest
  • Genotyping
  • Improvement and/or development of advanced experimental protocols
  • To develop methodologies for identifying and assaying species using molecular approaches
  • Project advice...
  • We provide a stool sampling kit for microbiome analysis.


BIOMNIGENE works in compliance with Good Laboratory Practice.






Healshape is a regenerative medicine company developing breast surgery products that allow regenerating women’ tissues from her own cells.


We develop a new generation of breast prosthesis who provide volume, shape and natural feeling on the long term through a simple surgery as the woman recovers her own tissues.  

We also work on the regeneration of nipple-areolar complex so that patients may benefit from a complete reconstruction after breast cancer.


Healshape wants to provide to millions of women in the world to choose their breast reconstruction or augmentation with confidence.